Replies to post #240007 on Biotech Values

[DewDiligence]

BLUE’s oncology spinoff—“2seventy bio”—begins_ trading_ tomorrow_as ‘TSVT’:

https://www.businesswire.com/news/home/20211104005298/en

BLUE residual gene-therapy company will continue to trade under the ‘BLUE’ ticker.